S-1: Processa Pharmaceuticals Launches Public Offering to Fund Cancer Therapy Development Amidst Going Concern Doubts

Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, is conducting a public offering of common stock and warrants to raise up to $7.0 million, aiming to fund its Phase 2 clinical trial for NGC-Cap and address its significant accumulated deficit and going concern issues.

Summary

• Processa Pharmaceuticals, Inc. is undertaking a "reasonable best efforts" public offering of up to 20,588,235 shares of common stock and accompanying common warrants.
• The offering also includes pre-funded warrants for purchasers who would exceed beneficial ownership limits, exercisable at a nominal price of $0.0001 per share.
• Placement agent warrants, representing 4.0% of the aggregate shares and pre-funded warrants sold, will also be issued with an exercise price of 125% of the public offering price.
• The assumed public offering price is $0.34 per share, based on the Nasdaq closing price on June 10, 2025.
• The company expects to raise approximately $6.3 million in net proceeds from this offering, assuming only common stock is sold.
• Proceeds are primarily intended for the Phase 2 clinical trial of NGC-Cap, working capital, and general corporate purposes.
• As of March 31, 2025, the company had cash and cash equivalents of $2.9 million and an accumulated deficit of approximately $90.1 million.
• The company explicitly states that its financial situation creates "substantial doubt" about its ability to continue as a going concern.
• Depending on the gross proceeds raised ($7.0M, $5.5M, or $4.0M), the company projects its capital needs will be satisfied into Q1 2026, end of 2025, or November 2025, respectively.
• The offering will result in immediate and substantial dilution of $0.04 per share to new investors.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol PCSA, but it received a deficiency letter on February 4, 2025, for failing to maintain a minimum bid price of $1.00, with a deadline of August 4, 2025, to regain compliance.
• There is no established public trading market for the Pre-Funded Warrants or Common Warrants, and the company does not expect one to develop, limiting their liquidity.

Sentiment

Score: 3

Explanation: The company is undertaking a critical capital raise to fund ongoing clinical trials and address its 'going concern' status. While the offering provides a lifeline, the significant accumulated deficit, low cash reserves, Nasdaq deficiency, and the 'best efforts' nature of the offering highlight severe financial distress and high execution risk. The dilution for new investors is also notable.

Positives

• The offering aims to secure funding for the continuation of the Phase 2 clinical trial for NGC-Cap, a key development for the company's pipeline.
• The company's strategy focuses on "Next Generation Cancer therapy (NGC) small molecules" by improving existing, well-understood cancer therapies to reduce toxicity and improve therapeutic effect, which is described as a "risk-mitigated strategy."
• The company utilizes a "proprietary Regulatory Science Approach" which it believes will increase the likelihood of regulatory approval.
• If clinical trials are successful and show better efficacy and tolerability than currently used drugs, the company anticipates "rapid and broad" commercial adoption.

Negatives

• The company has incurred recurring losses since inception and had an accumulated deficit of approximately $90.1 million as of March 31, 2025.
• The current cash and cash equivalents of $2.9 million as of March 31, 2025, are insufficient to fund operations beyond the short term without additional capital.
• The company explicitly states that its financial situation creates "substantial doubt" about its ability to continue as a going concern.
• The offering is a "best efforts" public offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital to meet its business plans.
• New investors will experience immediate and substantial dilution of $0.04 per share.
• The company received a Nasdaq deficiency letter on February 4, 2025, for its common stock bid price falling below $1.00, with a deadline of August 4, 2025, to regain compliance, risking delisting.
• There is no established public trading market for the Pre-Funded Warrants or Common Warrants, limiting their liquidity and potential value.
• The Common Warrants may not be exercisable until stockholder approval is obtained, and if not obtained, they will have no value.
• The company is involved in two lawsuits: one alleging fraud and negligent misrepresentation from a 2021 private offering, and another disputing a license agreement termination with Elion Oncology, Inc., both of which could have a material adverse effect.
• The company has never generated revenue from operations and has no immediate sales prospects.

Risks

• Inability to raise additional capital when needed, potentially forcing delays, reductions, or termination of development programs.
• Uncertainty regarding the actual amount of cash needed to fund activities, potentially leading to faster-than-expected depletion of financial resources.
• Risk of not achieving or sustaining profitability due to a history of operating losses and negative cash flow.
• Uncertainty of obtaining regulatory approval for drug candidates.
• Potential for significant liabilities and negative business impact from ongoing or future litigation, including substantial costs and diversion of management attention.
• Volatility in the per share price of common stock, potentially leading to securities litigation.
• Lack of a public trading market for Pre-Funded Warrants and Common Warrants, limiting their liquidity.
• Common Warrants may expire valueless if the market price of common stock does not exceed the exercise price.
• Risk that Common Warrants may not be exercisable if required stockholder approval is not obtained.
• Potential delisting of common stock from Nasdaq due to non-compliance with the minimum bid price rule.
• Reduced liquidity and trading activity if Nasdaq delists the securities.
• Future sales of common stock, warrants, or convertible securities may depress the stock price and hinder future capital raises.
• No anticipated cash dividends, requiring stockholders to rely on price appreciation for gains.
• FINRA sales practice requirements (Regulation Best Interest, suitability rules) may make it harder for broker-dealers to recommend the company's securities, reducing trading activity.
• Significant holders of Pre-Funded Warrants may be limited in their ability to exercise due to beneficial ownership limitations.

Future Outlook

Processa Pharmaceuticals anticipates needing to raise additional capital in the second half of 2025 to continue funding its operations and planned development of its Next Generation Cancer (NGC) drugs. The current offering, if successful in raising a minimum of $7.0 million gross proceeds, is expected to fund operations into the first quarter of 2026. The company aims to continue its Phase 2 clinical trial for NGC-Cap and potentially pursue in-licensing, acquisitions, or investments in complementary businesses, technologies, products, or assets.

Management Comments

• "We believe our strategy reduces clinical risk, regulatory risk and commercial risk."
• "Our risk-mitigated strategy is to identify existing cancer therapies where the mechanism of action is well understood and that are cornerstones of current treatment regimens, but are highly toxic, with side effects that are often treatment limiting."
• "We devise technologies to change the way the body metabolizes them, or the way they are distributed within the body, to improve the therapeutic effect and reduce toxicity."
• "We then efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach, which we believe will further increase the likelihood of regulatory approval."
• "Since the underlying drugs are already commonly used in cancer therapy, we believe, that if our clinical trials are successful, and are showing better efficacy and tolerability than the currently used drugs, the commercial adoption for our NGC therapies will be rapid and broad."
• "Assuming that we receive a minimum of $7.0 million of gross proceeds from this offering, we believe that the net proceeds from this offering, together with our cash on hand, will satisfy our capital needs into the first quarter of 2026 based on our current business plan."
• "We will need to raise additional capital to fund our operations and continue our planned development of our NGC drugs in the second half of 2025."

Industry Context

Processa Pharmaceuticals operates within the highly competitive and capital-intensive clinical-stage biopharmaceutical industry, specifically focusing on oncology. Their strategy of developing 'Next Generation Cancer therapies' by improving existing, well-understood drugs aims to mitigate risks associated with novel drug discovery. This approach positions them to potentially capitalize on established treatment paradigms if their modifications demonstrate superior efficacy and tolerability. However, the industry is characterized by high development costs, regulatory hurdles, and significant funding requirements, as evidenced by Processa's recurring losses and ongoing need for capital. The company's focus on improving existing therapies could offer a faster path to market compared to de novo drug development, but still faces substantial clinical and commercialization risks.

Comparison to Industry Standards

• The company's strategy of improving existing, well-understood cancer therapies (NGC small molecules) is a common approach in the biopharmaceutical industry to de-risk drug development, contrasting with companies focused solely on novel drug discovery which face higher clinical and regulatory risks.
• The stated "proprietary Regulatory Science Approach" is a claim of competitive advantage in navigating the FDA approval process, a critical and often lengthy bottleneck in the pharmaceutical industry.
• The company's financial position, with an accumulated deficit of $90.1 million and limited cash, is typical for clinical-stage biopharmaceutical companies that are pre-revenue and heavily invested in R&D, but the "going concern" warning indicates a more severe financial strain compared to peers with longer cash runways.
• The Nasdaq minimum bid price deficiency is a common challenge for smaller, early-stage biotech companies, indicating potential market skepticism or limited investor interest compared to more established industry players.
• The offering structure, including common stock, pre-funded warrants, and common warrants, is a standard financing mechanism for biotech companies seeking to raise capital while managing investor beneficial ownership limits and providing upside potential through warrants.

Corporate Governance

Legal Proceedings

• On December 22, 2024, two investors from the February 2021 private offering filed a lawsuit alleging fraud and negligent misrepresentation, seeking monetary damages.
• On May 10, 2024, the company filed a lawsuit against Elion Oncology, Inc. disputing the purported termination of a license agreement, which is subject to counterclaims by Elion.

Related Party Transactions

• The placement agent fees include a reduced cash fee of 3.0% for gross proceeds received from "Company Investors" (current directors and officers) exceeding $3.0 million, compared to the standard 7.0%.
• Placement Agent Warrants are not issued with respect to up to $3 million of gross proceeds received from Company Investors.
• The document states that, except as set forth on Schedule 3.1(r) (not provided), none of the officers or directors or employees are party to transactions with the company exceeding $120,000, other than for salary, expense reimbursement, and other employee benefits.

Stakeholder Impact

• Shareholders: Significant dilution for new investors. Existing shareholders face potential further dilution from warrant exercises and future capital raises. The Nasdaq deficiency and "going concern" warning pose risks to share value and continued trading.
• Employees/Management: Employment agreements for key officers are in place. Lock-up agreements restrict their ability to sell shares for 90 days post-offering.
• Creditors: The "going concern" warning indicates increased risk for creditors if the company cannot secure sufficient funding.
• Placement Agent (H.C. Wainwright & Co., LLC): Will receive cash fees (7.0% or 3.0% for Company Investors) and Placement Agent Warrants (4.0% of shares/pre-funded warrants sold).

Next Steps

• Continue the Phase 2 clinical trial of NGC-Cap.
• Raise additional capital in the second half of 2025 to fund operations and continue planned development of NGC drugs.
• Seek stockholder approval for the issuance of shares upon exercise of Common Warrants (if required by Nasdaq rules), with subsequent meetings every 90 days if not obtained initially.
• Regain compliance with Nasdaq's minimum bid price requirement by August 4, 2025, to avoid delisting.
• Potentially in-license, acquire, or invest in complementary businesses, technologies, products, or assets.
• Officers and directors are subject to a 90-day lock-up period post-closing.
• The company is subject to a 60-day lock-up on new equity issuances post-closing (with exceptions).
• The company is prohibited from Variable Rate Transactions for six months post-closing (with exceptions after 90 days).

Key Dates

Recommendation

Keywords

Processa Pharmaceuticals, PCSA, SEC S-1, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, Biopharmaceutical, Clinical Stage, Cancer Therapy, NGC-Cap, Nasdaq Listing, Capital Raise, Dilution, Going Concern, Risk Factors, Drug Development, Pharmaceuticals, Oncology